Global Acute Myeloid Leukemia Market Size Study & Forecast, By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Other Chemotherapies), and Regional Analysis, 2023-2030
Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.
In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC’s ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.
Major market players included in this report are:
Novartis AG
Genmab AS
Otsuka Holdings Co. Ltd
Sanofi-Aventis (Genzyme Corporation)
Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sunesis Pharmaceuticals Inc.
Astellas Pharma Inc.
Oncolyze Inc.
Recent Developments in the Market:
In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.
Global Acute Myeloid Leukemia Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Chemotherapy, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Chemotherapy:
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Other Chemotherapies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC’s ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.
Major market players included in this report are:
Novartis AG
Genmab AS
Otsuka Holdings Co. Ltd
Sanofi-Aventis (Genzyme Corporation)
Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sunesis Pharmaceuticals Inc.
Astellas Pharma Inc.
Oncolyze Inc.
Recent Developments in the Market:
In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.
Global Acute Myeloid Leukemia Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Chemotherapy, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Chemotherapy:
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Other Chemotherapies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ACUTE MYELOID LEUKEMIA MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ACUTE MYELOID LEUKEMIA MARKET DYNAMICS
3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of acute myeloid leukemia
3.1.1.2. Rising geriatric population
3.1.2. Market Challenges
3.1.2.1. Stringent regulations on drugs
3.1.2.2. Complications related to chemotherapy
3.1.3. Market Opportunities
3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
3.1.3.2. Increasing investments in research and development
CHAPTER 4. GLOBAL ACUTE MYELOID LEUKEMIA MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ACUTE MYELOID LEUKEMIA MARKET, BY CHEMOTHERAPY
5.1. Market Snapshot
5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
5.4.1. Cytarabine
5.4.2. Anthracycline Drugs
5.4.3. Alkylating Agents
5.4.4. Anti-metabolites
5.4.5. Tyrosine Kinase Inhibitors
5.4.6. Hormonal Therapy
5.4.7. Other Chemotherapies
CHAPTER 6. GLOBAL ACUTE MYELOID LEUKEMIA MARKET, REGIONAL ANALYSIS
6.1. Top Leading Countries
6.2. Top Emerging Countries
6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
6.4. North America Acute Myeloid Leukemia Market
6.4.1. U.S. Acute Myeloid Leukemia Market
6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
6.4.2. Canada Acute Myeloid Leukemia Market
6.5. Europe Acute Myeloid Leukemia Market Snapshot
6.5.1. U.K. Acute Myeloid Leukemia Market
6.5.2. Germany Acute Myeloid Leukemia Market
6.5.3. France Acute Myeloid Leukemia Market
6.5.4. Spain Acute Myeloid Leukemia Market
6.5.5. Italy Acute Myeloid Leukemia Market
6.5.6. Rest of Europe Acute Myeloid Leukemia Market
6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
6.6.1. China Acute Myeloid Leukemia Market
6.6.2. India Acute Myeloid Leukemia Market
6.6.3. Japan Acute Myeloid Leukemia Market
6.6.4. Australia Acute Myeloid Leukemia Market
6.6.5. South Korea Acute Myeloid Leukemia Market
6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
6.7. Latin America Acute Myeloid Leukemia Market Snapshot
6.7.1. Brazil Acute Myeloid Leukemia Market
6.7.2. Mexico Acute Myeloid Leukemia Market
6.8. Middle East & Africa Acute Myeloid Leukemia Market
6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
6.8.2. South Africa Acute Myeloid Leukemia Market
6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market
CHAPTER 7. COMPETITIVE INTELLIGENCE
7.1. Key Company SWOT Analysis
7.1.1. Company
7.1.2. Company
7.1.3. Company
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Novartis AG
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Recent Developments
7.3.2. Genmab AS
7.3.3. Otsuka Holdings Co. Ltd
7.3.4. Sanofi-Aventis (Genzyme Corporation)
7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.3.6. Pfizer Inc.
7.3.7. F. Hoffmann-La Roche Ltd
7.3.8. Sunesis Pharmaceuticals Inc.
7.3.9. Astellas Pharma Inc.
7.3.10. Oncolyze Inc.
CHAPTER 8. RESEARCH PROCESS
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ACUTE MYELOID LEUKEMIA MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ACUTE MYELOID LEUKEMIA MARKET DYNAMICS
3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of acute myeloid leukemia
3.1.1.2. Rising geriatric population
3.1.2. Market Challenges
3.1.2.1. Stringent regulations on drugs
3.1.2.2. Complications related to chemotherapy
3.1.3. Market Opportunities
3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
3.1.3.2. Increasing investments in research and development
CHAPTER 4. GLOBAL ACUTE MYELOID LEUKEMIA MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ACUTE MYELOID LEUKEMIA MARKET, BY CHEMOTHERAPY
5.1. Market Snapshot
5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
5.4.1. Cytarabine
5.4.2. Anthracycline Drugs
5.4.3. Alkylating Agents
5.4.4. Anti-metabolites
5.4.5. Tyrosine Kinase Inhibitors
5.4.6. Hormonal Therapy
5.4.7. Other Chemotherapies
CHAPTER 6. GLOBAL ACUTE MYELOID LEUKEMIA MARKET, REGIONAL ANALYSIS
6.1. Top Leading Countries
6.2. Top Emerging Countries
6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
6.4. North America Acute Myeloid Leukemia Market
6.4.1. U.S. Acute Myeloid Leukemia Market
6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
6.4.2. Canada Acute Myeloid Leukemia Market
6.5. Europe Acute Myeloid Leukemia Market Snapshot
6.5.1. U.K. Acute Myeloid Leukemia Market
6.5.2. Germany Acute Myeloid Leukemia Market
6.5.3. France Acute Myeloid Leukemia Market
6.5.4. Spain Acute Myeloid Leukemia Market
6.5.5. Italy Acute Myeloid Leukemia Market
6.5.6. Rest of Europe Acute Myeloid Leukemia Market
6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
6.6.1. China Acute Myeloid Leukemia Market
6.6.2. India Acute Myeloid Leukemia Market
6.6.3. Japan Acute Myeloid Leukemia Market
6.6.4. Australia Acute Myeloid Leukemia Market
6.6.5. South Korea Acute Myeloid Leukemia Market
6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
6.7. Latin America Acute Myeloid Leukemia Market Snapshot
6.7.1. Brazil Acute Myeloid Leukemia Market
6.7.2. Mexico Acute Myeloid Leukemia Market
6.8. Middle East & Africa Acute Myeloid Leukemia Market
6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
6.8.2. South Africa Acute Myeloid Leukemia Market
6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market
CHAPTER 7. COMPETITIVE INTELLIGENCE
7.1. Key Company SWOT Analysis
7.1.1. Company
7.1.2. Company
7.1.3. Company
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Novartis AG
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Recent Developments
7.3.2. Genmab AS
7.3.3. Otsuka Holdings Co. Ltd
7.3.4. Sanofi-Aventis (Genzyme Corporation)
7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.3.6. Pfizer Inc.
7.3.7. F. Hoffmann-La Roche Ltd
7.3.8. Sunesis Pharmaceuticals Inc.
7.3.9. Astellas Pharma Inc.
7.3.10. Oncolyze Inc.
CHAPTER 8. RESEARCH PROCESS
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Acute Myeloid Leukemia Market, report scope
TABLE 2. Global Acute Myeloid Leukemia Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Acute Myeloid Leukemia Market estimates & forecasts by Chemotherapy 2020-2030 (USD Billion)
TABLE 4. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 5. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. U.S. Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 16. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. Canada Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 18. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. UK Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 21. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. Germany Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 24. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. France Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 27. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. Italy Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 30. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Spain Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 33. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. RoE Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 36. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. China Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 39. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. India Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 42. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. Japan Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 45. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. South Korea Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 48. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. Australia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 51. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 54. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. Brazil Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 57. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Mexico Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 60. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. RoLA Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 63. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. Saudi Arabia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 66. South Africa Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. RoMEA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. List of secondary sources, used in the study of global Acute Myeloid Leukemia Market
TABLE 69. List of primary sources, used in the study of global Acute Myeloid Leukemia Market
TABLE 70. Years considered for the study
TABLE 71. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Acute Myeloid Leukemia Market, report scope
TABLE 2. Global Acute Myeloid Leukemia Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Acute Myeloid Leukemia Market estimates & forecasts by Chemotherapy 2020-2030 (USD Billion)
TABLE 4. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 5. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. U.S. Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 16. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. Canada Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 18. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. UK Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 21. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. Germany Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 24. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. France Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 27. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. Italy Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 30. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Spain Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 33. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. RoE Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 36. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. China Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 39. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. India Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 42. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. Japan Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 45. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. South Korea Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 48. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. Australia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 51. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 54. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. Brazil Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 57. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Mexico Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 60. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. RoLA Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 63. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. Saudi Arabia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 66. South Africa Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. RoMEA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. List of secondary sources, used in the study of global Acute Myeloid Leukemia Market
TABLE 69. List of primary sources, used in the study of global Acute Myeloid Leukemia Market
TABLE 70. Years considered for the study
TABLE 71. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Acute Myeloid Leukemia Market, research methodology
FIG 2. Global Acute Myeloid Leukemia Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Acute Myeloid Leukemia Market, key trends 2022
FIG 5. Global Acute Myeloid Leukemia Market, growth prospects 2023-2030
FIG 6. Global Acute Myeloid Leukemia Market, porters 5 force model
FIG 7. Global Acute Myeloid Leukemia Market, pest analysis
FIG 8. Global Acute Myeloid Leukemia Market, value chain analysis
FIG 9. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Acute Myeloid Leukemia Market, regional snapshot 2020 & 2030
FIG 15. North America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 16. Europe Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Acute Myeloid Leukemia Market, research methodology
FIG 2. Global Acute Myeloid Leukemia Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Acute Myeloid Leukemia Market, key trends 2022
FIG 5. Global Acute Myeloid Leukemia Market, growth prospects 2023-2030
FIG 6. Global Acute Myeloid Leukemia Market, porters 5 force model
FIG 7. Global Acute Myeloid Leukemia Market, pest analysis
FIG 8. Global Acute Myeloid Leukemia Market, value chain analysis
FIG 9. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Acute Myeloid Leukemia Market, regional snapshot 2020 & 2030
FIG 15. North America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 16. Europe Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
